Covid vaccine maker BioNTech offers cheap biotech play given huge cash reserves

The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise ...

Co-founders behind pioneering Covid vaccine to step down from BioNTech

The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...
Fierce Biotech

BioNTech's CEO, CMO prep departure to set up next-gen mRNA company

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on ...

BioNTech falls on outlook, departure of co-founders

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

Scientists behind COVID-19 vaccine will depart BioNTech

The company’s co-founders said they are leaving to start a new mRNA-based company.
Fierce Biotech

Chutes & Ladders—BioNTech founders will depart to pioneer new company

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

BioNTech's founding couple to quit to set up new venture

By Ludwig Burger FRANKFURT, March 10 (Reuters) - The two co-founders and leading executives of Germany's BioNTech will leave ...

BioNTech founders step down to start new venture

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...
Seeking Alpha

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...